Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology firm focused on hearing and balance treatments, announced that CEO Laurence Reid, Ph.D., will speak at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET. Interested parties can access the live webcast via the Decibel website, with an archived replay available for 90 days post-event. The company aims to develop transformative therapies, including its lead program, DB-OTO, targeting congenital hearing loss.

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m. ET.

A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com  
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com  
617-834-0936

FAQ

What is Decibel Therapeutics planning for February 17, 2022?

Decibel Therapeutics will have CEO Laurence Reid participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

Where can I watch the Decibel Therapeutics fireside chat?

You can watch the live webcast of the Decibel Therapeutics fireside chat on their Investors section of the website.

What is the main focus of Decibel Therapeutics?

Decibel Therapeutics focuses on discovering and developing treatments to restore and improve hearing and balance.

What is DB-OTO and its significance?

DB-OTO is Decibel's lead gene therapy program aimed at treating congenital, monogenic hearing loss.

How long will the replay of the Decibel Therapeutics webcast be available?

The archived replay of the webcast will be available for approximately 90 days after the event.